Nilotinib

Nilotinib binds selectively to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, inhibiting its activity. This blocks downstream signaling that promotes cell proliferation and survival, while also affecting related kinases such as PDGFR and c‑KIT, leading to reduced growth of malignant cells.

The dose of Nilotinib is individualized by the prescribing physician based on the patient’s clinical status, disease phase, and tolerability. Dosing regimens are determined by the treating oncologist and should follow the approved prescribing information.

The safety of Nilotinib in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made in consultation with a specialist.

To request Nilotinib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency against many resistant BCR‑ABL mutations compared with first‑generation agents like imatinib. Its distinct binding profile may offer efficacy in patients who have progressed on earlier TKIs, though safety and tolerability profiles differ.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original container. Protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal. Patients should swallow the tablets whole with water and follow the dosing schedule prescribed by their healthcare provider, adhering to any food‑related instructions.

Serious risks include cardiovascular events such as arterial occlusion, QT‑interval prolongation that can lead to arrhythmias, severe hepatic injury, and pancreatitis. Patients should be monitored regularly for these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Nilotinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with uncontrolled cardiac disease, severe hepatic impairment, or those taking strong CYP3A4 inhibitors, unless a risk‑benefit assessment supports use.